

Wolfgang Andreas Weber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6154122/publications.pdf>

Version: 2024-02-01

94
papers

4,922
citations

136885

32
h-index

98753

67
g-index

98
all docs

98
docs citations

98
times ranked

4672
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of Response to Preoperative Chemotherapy in Adenocarcinomas of the Esophagogastric Junction by Metabolic Imaging. <i>Journal of Clinical Oncology</i> , 2001, 19, 3058-3065.	0.8	682
2	O-(2-[¹⁸ F]Fluoroethyl)-L-tyrosine and L-[methyl- ¹¹ C]methionine uptake in brain tumours: initial results of a comparative study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 542-549.	3.3	353
3	FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 288-295.	3.3	290
4	Detection Efficacy of ¹⁸ F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 362-368.	2.8	238
5	An Interindividual Comparison of O-(2-[¹⁸ F]Fluoroethyl)-L-Tyrosine (FET) and L-[Methyl- ¹¹ C]Methionine (MET) PET in Patients With Brain Gliomas and Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1049-1058.	0.4	222
6	Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with ¹⁷⁷ Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 75, 920-926.	0.9	206
7	Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1248-1252.	2.8	197
8	Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine. <i>Journal of Nuclear Medicine</i> , 2019, 60, 13S-19S.	2.8	172
9	Matched-Pair Comparison of ⁶⁸ Ga-PSMA-11 PET/CT and ¹⁸ F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 51-57.	2.8	161
10	Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a ⁶⁸ Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1743-1749.	2.8	159
11	O-(2-[¹⁸ F]Fluoroethyl)-L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 1039-1046.	3.3	131
12	Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. <i>European Urology</i> , 2021, 79, 343-350.	0.9	128
13	Preoperative Evaluation of Pancreatic Masses with Positron Emission Tomography Using ¹⁸ F-fluorodeoxyglucose: Diagnostic Limitations. <i>World Journal of Surgery</i> , 2000, 24, 1121-1129.	0.8	102
14	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology</i> , The, 2018, 19, e696-e708.	5.1	90
15	Imaging of esophageal and gastric cancer. <i>Seminars in Oncology</i> , 2004, 31, 530-541.	0.8	84
16	qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using ⁶⁸ Ga-PSMA11 PET/CT. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1277-1283.	2.8	82
17	Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer. <i>European Urology</i> , 2019, 76, 517-523.	0.9	81
18	Whole-body positron emission tomography in clinical oncology: Comparison between attenuation-corrected and uncorrected images. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 1091-1098.	2.2	80

#	ARTICLE	IF	CITATIONS
19	¹⁸ F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 696-701.	2.8	67
20	The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. <i>Journal of Nuclear Medicine</i> , 2020, 61, 263S-272S.	2.8	67
21	FDG/PET-CT-Based Lymph Node Atlas in Breast Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 574-582.	0.4	50
22	Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using ⁶⁸ Ga-NOTA-anti-MMR nanobody: non-invasive imaging of atherosclerotic plaques. <i>EJNMMI Research</i> , 2019, 9, 5.	1.1	46
23	Performance of [⁶⁸ Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2925-2934.	3.3	43
24	Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. <i>European Urology</i> , 2022, 82, 156-160.	0.9	43
25	Efficacy and Safety of ¹⁷⁷ Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. <i>European Urology</i> , 2020, 78, 148-154.	0.9	39
26	The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma. <i>Molecular Cell</i> , 2021, 81, 1170-1186.e10.	4.5	39
27	Imaging of cardiac fibroblast activation in a patient after acute myocardial infarction using ⁶⁸ Ga-FAPI-04. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 2254-2261.	1.4	39
28	The AQARA Principle: Proposing Standard Requirements for Radionuclide-Based Images in Medical Journals. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1-2.	2.8	38
29	Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, ¹⁸ F-rhPSMA-7, in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 702-709.	2.8	38
30	The added value of PSMA PET/MR radiomics for prostate cancer staging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 527-538.	3.3	38
31	Irradiation of regional lymph node areas in breast cancer — Dose evaluation according to the Z0011, AMAROS, EORTC 10981-22023 and MA-20 field design. <i>Radiotherapy and Oncology</i> , 2020, 142, 195-201.	0.3	37
32	Histologically Confirmed Diagnostic Efficacy of ¹⁸ F-rhPSMA-7 PET for N-Staging of Patients with Primary High-Risk Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 710-715.	2.8	34
33	Early Prostate-Specific Antigen Changes and Clinical Outcome After ¹⁷⁷ Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1476-1483.	2.8	34
34	CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1765-1771.	2.8	34
35	Relationship between production of epidermal growth factor receptors, gene amplification, and chromosome 7 translocation in variant A431 cells. <i>Somatic Cell and Molecular Genetics</i> , 1985, 11, 309-318.	0.7	33
36	Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy—results from a prospective trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1046-1055.	3.3	32

#	ARTICLE	IF	CITATIONS
37	Early Experience of Rechallenge ¹⁷⁷ Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 644-648.	2.8	29
38	Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.263072.	2.8	28
39	Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET. <i>Radiation Oncology</i> , 2018, 13, 159.	1.2	26
40	Diffusion-weighted MRI and ADC versus FET-PET and Gd1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma. <i>Radiotherapy and Oncology</i> , 2019, 130, 121-131.	0.3	24
41	Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes. <i>Journal of Clinical Medicine</i> , 2020, 9, 2130.	1.0	24
42	Whole-body uptake classification and prostate cancer staging in ⁶⁸ Ga-PSMA-11 PET/CT using dual-tracer learning. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 517-526.	3.3	23
43	Have we achieved adequate recommendations for target volume definitions in anal cancer? A PET imaging based patterns of failure analysis in the context of established contouring guidelines. <i>BMC Cancer</i> , 2019, 19, 742.	1.1	22
44	Development of a high affinity Anticalin [®] directed against human CD98hc for theranostic applications. <i>Theranostics</i> , 2020, 10, 2172-2187.	4.6	22
45	Synthesis and Preclinical Evaluation of a ⁶⁸ Ga-Labeled Adnectin, ⁶⁸ Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1228-1234.	2.8	21
46	Somatostatin Receptor Imaging of Neuroendocrine Tumors: From Agonists to Antagonists. <i>Journal of Nuclear Medicine</i> , 2018, 59, 907-908.	2.8	20
47	Can the Injected Dose Be Reduced in ⁶⁸ Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?. <i>Journal of Nuclear Medicine</i> , 2020, 61, 189-193.	2.8	19
48	Effective control of tumor growth through spatial and temporal control of theranostic sodium iodide symporter (<i>NIS</i>) gene expression using a heat-inducible gene promoter in engineered mesenchymal stem cells. <i>Theranostics</i> , 2020, 10, 4490-4506.	4.6	19
49	PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial. <i>Cancers</i> , 2021, 13, 5795.	1.7	19
50	Immune response after striatal engraftment of fetal neuronal cells in patients with Huntington's disease: Consequences for cerebral transplantation programs. <i>Clinical and Experimental Neuroimmunology</i> , 2011, 2, 25-32.	0.5	17
51	Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation. <i>Theranostics</i> , 2020, 10, 9395-9406.	4.6	16
52	Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using ¹⁹ F/ ¹⁷⁷ Lu-rhPSMA-7.3 and ¹⁷⁷ Lu-PSMA I&T. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1106-1111.	2.8	16
53	Automated synthesis of [¹⁸ F]Ga-rhPSMA-7/ -7.3: results, quality control and experience from more than 200 routine productions. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 4.	1.8	16
54	Imaging atherosclerotic plaques by targeting Galectin-3 and activated macrophages using (⁸⁹ Zr)-DFO- Galectin3-F(ab') ₂ mAb. <i>Theranostics</i> , 2021, 11, 1864-1876.	4.6	16

#	ARTICLE	IF	CITATIONS
55	Regional Hyperthermia Enhances Mesenchymal Stem Cell Recruitment to Tumor Stroma: Implications for Mesenchymal Stem Cell-Based Tumor Therapy. <i>Molecular Therapy</i> , 2021, 29, 788-803.	3.7	16
56	Value of PET imaging for radiation therapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1-23.	1.0	16
57	Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients. <i>EJNMMI Research</i> , 2021, 11, 77.	1.1	16
58	Clinical PET/MR. <i>Recent Results in Cancer Research</i> , 2020, 216, 747-764.	1.8	16
59	Integration of PET-imaging into radiotherapy treatment planning for low-grade meningiomas improves outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1391-1399.	3.3	15
60	Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT. <i>British Journal of Cancer</i> , 2022, 126, 1271-1279.	2.9	15
61	Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer: Results from a Prospective Imaging Trial. <i>Journal of Nuclear Medicine</i> , 2021, 62, 471-478.	2.8	14
62	Detection Efficacy of ¹⁸ F- α -PSMA-7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1719-1726.	2.8	14
63	Room Temperature Al ¹⁸ F Labeling of 2- α -Aminomethylpiperidine-Based Chelators for PET Imaging. <i>ChemMedChem</i> , 2020, 15, 284-292.	1.6	13
64	Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in ¹⁷⁷ Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment. <i>Journal of Nuclear Medicine</i> , 2021, 62, 92-98.	2.8	13
65	Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 6-14.	2.8	13
66	PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy. <i>EJNMMI Research</i> , 2021, 11, 76.	1.1	12
67	Development of a Chimeric Antigen-Binding Fragment Directed Against Human Galectin-3 and Validation as an Immuno-Positron Emission Tomography Tracer for the Sensitive <i>In Vivo</i> Imaging of Thyroid Cancer. <i>Thyroid</i> , 2020, 30, 1314-1326.	2.4	11
68	Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET/CT: a bi-centric analysis. <i>EJNMMI Research</i> , 2019, 9, 103.	1.1	11
69	Selective sodium iodide symporter (NIS) gene therapy of glioblastoma mediated by EGFR-targeted lipopolyplexes. <i>Molecular Therapy - Oncolytics</i> , 2021, 23, 432-446.	2.0	11
70	Positron Emission tomography imaging in urological oncology: Current aspects and developments. <i>International Journal of Urology</i> , 2018, 25, 912-921.	0.5	10
71	The sodium iodide symporter (NIS) as theranostic gene: its emerging role in new imaging modalities and non-viral gene therapy. <i>EJNMMI Research</i> , 2022, 12, 25.	1.1	10
72	Neuroimaging for Radiation Therapy of Brain Tumors. <i>Topics in Magnetic Resonance Imaging</i> , 2019, 28, 63-71.	0.7	9

#	ARTICLE	IF	CITATIONS
73	Pitfalls in Ga-68-PSMA-PET/CT: incidental finding of parathyroid adenoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1041-1041.	3.3	9
74	RSV: Robotic Sonography for Thyroid Volumetry. <i>IEEE Robotics and Automation Letters</i> , 2022, 7, 3342-3348.	3.3	9
75	Almost 10 years of PET/MR attenuation correction: the effect on lesion quantification with PSMA: clinical evaluation on 200 prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 543-553.	3.3	8
76	Is Hypoxia a Factor Influencing PSMA-Directed Radioligand Therapy? An In Silico Study on the Role of Chronic Hypoxia in Prostate Cancer. <i>Cancers</i> , 2021, 13, 3429.	1.7	8
77	In vivo Visualization of M2 Macrophages in the Myocardium After Myocardial Infarction (MI) Using 68Ga-NOTA-Anti-MMR Nb: Targeting Mannose Receptor (MR, CD206) on M2 Macrophages. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 889963.	1.1	7
78	Exceptional 4-year response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2212-2213.	3.3	5
79	Positive predictive value and correct detection rate of ¹⁸ F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.255661.	2.8	5
80	Effective rational humanization of a PASylated anti-galectin-3 Fab for the sensitive PET imaging of thyroid cancer in vivo. <i>Scientific Reports</i> , 2021, 11, 7358.	1.6	5
81	The Influence of Specific Activity on the Biodistribution of 18F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262471.	2.8	5
82	Pre-test 68Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomy validation of a prediction model. <i>EJNMMI Research</i> , 2020, 10, 6.	1.1	5
83	Temporary reactive response of axillary lymph nodes to COVID-19 vaccination on ¹⁸ F-rhPSMA-7.3 PET/CT in patients with prostate cancer. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.263758.	2.8	5
84	Toward Novel [18F]Fluorine-Labeled Radiotracers for the Imaging of α -Synuclein Fibrils. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 830704.	1.7	5
85	Nuclear Molecular Imaging of Cardiac Remodeling after Myocardial Infarction. <i>Pharmaceuticals</i> , 2022, 15, 183.	1.7	4
86	Initial evaluation of [18F]-FACBC for PET imaging of multiple myeloma. <i>EJNMMI Research</i> , 2022, 12, 4.	1.1	4
87	Preclinical biodistribution and dosimetry and human biodistribution comparing 18F-rhPSMA-7 and single isomer 18F-rhPSMA-7.3. <i>EJNMMI Research</i> , 2022, 12, 8.	1.1	4
88	The value of plasma hypoxia markers for predicting imaging-based hypoxia in patients with head-and-neck cancers undergoing definitive chemoradiation. <i>Clinical and Translational Radiation Oncology</i> , 2022, 33, 120-127.	0.9	3
89	Interim PSMA PET/CT for response evaluation during LuPSMA treatment in mCRPC (INTERIM PET): An explorative, multicenter study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5066-5066.	0.8	2
90	Value of PET imaging for radiation therapy. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, 60, 326-343.	0.3	2

#	ARTICLE	IF	CITATIONS
91	CXCR4-Targeted Positron Emission Tomography Imaging of Central Nervous System B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 2900-2900.	0.6	1
92	Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP): An international multicenter study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 42-42.	0.8	1
93	Reply: Radioguided Surgery. <i>Journal of Nuclear Medicine</i> , 2021, 62, 592-592.	2.8	0
94	Comparison of the distribution of lymph node metastases compared to healthy lymph nodes in breast cancer. <i>Radiation Oncology</i> , 2022, 17, 27.	1.2	0